• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEls) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension. Comparative Effectiveness Review, Number 10
【24h】

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEls) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension. Comparative Effectiveness Review, Number 10

机译：血管紧张素转换酶抑制剂（aCEls）和血管紧张素II受体拮抗剂（aRBs）治疗原发性高血压的疗效比较。比较效力评估，第10号

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This review summarizes the evidence on the comparative long-term benefits and harms of ACEIs versus ARBs, focusing on their use for treating essential hypertension in adults. Key questions addressed are: 1. For adult patients with essential hypertension, how do ACEIs and ARBs differ in blood pressure control, cardiovascular risk reduction, cardiovascular events, quality of life, and other outcomes 2. For adult patients with essential hypertension, how do ACEIs and ARBs differ in safety, adverse events, tolerability, persistence, and adherence 3.Are there subgroups of patients based on demographic characteristics (age, racial and ethnic groups, sex), use of other medications concurrently, or comorbidities for which ACEIs or ARBs are more effective, associated with fewer adverse events, or better tolerated

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号